- Home
- ALLE vs EXEL Comparison
ALLE vs EXEL Comparison
Compare ALLE & EXEL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ALLE
- EXEL
- Stock Information
- Founded
- ALLE 2013
- EXEL 1994
- Country
- ALLE Ireland
- EXEL United States
- Employees
- ALLE N/A
- EXEL N/A
- Industry
- ALLE Diversified Commercial Services
- EXEL Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- ALLE Consumer Discretionary
- EXEL Health Care
- Exchange
- ALLE Nasdaq
- EXEL Nasdaq
- Market Cap
- ALLE 10.9B
- EXEL 9.4B
- IPO Year
- ALLE N/A
- EXEL 2000
- Fundamental
- Price
- ALLE $127.17
- EXEL $36.85
- Analyst Decision
- ALLE Hold
- EXEL Buy
- Analyst Count
- ALLE 6
- EXEL 18
- Target Price
- ALLE $138.33
- EXEL $37.24
- AVG Volume (30 Days)
- ALLE 985.2K
- EXEL 2.5M
- Earning Date
- ALLE 02-18-2025
- EXEL 02-11-2025
- Dividend Yield
- ALLE 1.61%
- EXEL N/A
- EPS Growth
- ALLE 11.44
- EXEL 170.77
- EPS
- ALLE 6.82
- EXEL 1.76
- Revenue
- ALLE $3,772,200,000.00
- EXEL $2,168,701,000.00
- Revenue This Year
- ALLE $5.24
- EXEL $5.36
- Revenue Next Year
- ALLE $3.67
- EXEL $10.59
- P/E Ratio
- ALLE $18.55
- EXEL $20.87
- Revenue Growth
- ALLE 3.33
- EXEL 18.49
- 52 Week Low
- ALLE $113.27
- EXEL $20.14
- 52 Week High
- ALLE $156.10
- EXEL $37.59
- Technical
- Relative Strength Index (RSI)
- ALLE 41.23
- EXEL 65.59
- Support Level
- ALLE $124.19
- EXEL $34.01
- Resistance Level
- ALLE $134.25
- EXEL $35.46
- Average True Range (ATR)
- ALLE 2.43
- EXEL 1.09
- MACD
- ALLE -0.33
- EXEL 0.36
- Stochastic Oscillator
- ALLE 29.60
- EXEL 95.70
About ALLE Allegion plc
Allegion is a global security products company with a portfolio of leading brands such as Schlage, Von Duprin, and LCN. The Ireland-domiciled company was created via a spinoff transaction from Ingersoll-Rand in December 2013. In fiscal 2023, Allegion generated 75% of sales in the United States. The company primarily competes with Sweden-based Assa Abloy and Switzerland-based Dormakaba.
About EXEL Exelixis Inc.
Exelixis is a biopharmaceutical firm that discovers, develops, and commercializes treatments for cancer. Its lead molecule, cabozantinib, is indicated for the treatment of patients with metastatic medullary thyroid cancer under the name Cometriq and for the treatment of kidney and liver cancer under the name Cabometyx. Exelixis and its partner Roche have also brought Cotellic to market for the treatment of melanoma.